Figure 2.
Synergistic antitumor activity of BGs with oxaliplatin in the murine carcinosis model CT26. (A) Male BALB/c mice were injected i.p. with 1 × 105 CT26 cells on day 0 (D0) and treated according to TS1 (n = 4 per group). (B) On day 10 mice were dissected, the tumors visually identified, collected and weighed. Statistical significance was calculated by nonparametric one-way ANOVA and Bonferroni posttest (* p < 0.05, significantly different from solvent group). (C) In a follow-up experiment, mice were treated with TS1 and dissection was performed on day 13. Median tumor and spleen weights were evaluated. Statistical significance was calculated by unpaired t test (** p < 0.01). (D) The second, another treatment group continued therapy as shown in TS2. (E) In these animals, treatment resulted in significantly prolonged survival (**p < 0.01 calculated by Log-rank test and Mantel-Cox posttest). One of the animals experienced complete remission. This cured mouse was subsequently rechallenged i.p. with CT26 cells (1 × 105) on day 80 (indicated by the arrow).